Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

1.

Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.

Mück W, Ochmann K, Mazzu A, Lettieri J.

J Int Med Res. 1999 May-Jun;27(3):107-14.

PMID:
10505300
[PubMed - indexed for MEDLINE]
2.

Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening.

Mück W, Frey R, Unger S, Voith B.

Int J Clin Pharmacol Ther. 2000 Jun;38(6):298-303.

PMID:
10890578
[PubMed - indexed for MEDLINE]
3.

Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.

Mück W, Ochmann K, Rohde G, Unger S, Kuhlmann J.

Eur J Clin Pharmacol. 1998 Feb;53(6):469-73.

PMID:
9551706
[PubMed - indexed for MEDLINE]
4.

Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.

Mück W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, Kuhlmann J.

Int J Clin Pharmacol Ther. 1997 Jun;35(6):255-60.

PMID:
9208342
[PubMed - indexed for MEDLINE]
5.

Influence of cholestyramine on the pharmacokinetics of cerivastatin.

Mück W, Ritter W, Frey R, Wetzelsberger N, Lücker PW, Kuhlmann J.

Int J Clin Pharmacol Ther. 1997 Jun;35(6):250-4.

PMID:
9208341
[PubMed - indexed for MEDLINE]
6.

Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.

Weber P, Lettieri JT, Kaiser L, Mazzu AL.

Clin Ther. 1999 Sep;21(9):1563-75.

PMID:
10509851
[PubMed - indexed for MEDLINE]
7.

Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults.

Mazzu AL, Lettieri JT, Kelly E, Vargas R, Marbury T, Liu MC, Sundaresan P.

Eur J Clin Pharmacol. 2000 Apr;56(1):69-74.

PMID:
10853881
[PubMed - indexed for MEDLINE]
8.

Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers.

Mazzu A, Lettieri J, Kaiser L, Mullican W, Heller AH.

J Clin Pharmacol. 1998 Aug;38(8):715-9.

PMID:
9725547
[PubMed - indexed for MEDLINE]
9.

Gemfibrozil greatly increases plasma concentrations of cerivastatin.

Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ.

Clin Pharmacol Ther. 2002 Dec;72(6):685-91.

PMID:
12496749
[PubMed - indexed for MEDLINE]
10.

Effect of itraconazole on cerivastatin pharmacokinetics.

Kantola T, Kivistö KT, Neuvonen PJ.

Eur J Clin Pharmacol. 1999 Jan;54(11):851-5.

PMID:
10027660
[PubMed - indexed for MEDLINE]
11.

Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.

Mück W, Ritter W, Dietrich H, Frey R, Kuhlmann J.

Int J Clin Pharmacol Ther. 1997 Jun;35(6):261-4.

PMID:
9208343
[PubMed - indexed for MEDLINE]
12.

Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.

von Keutz E, Schlüter G.

Am J Cardiol. 1998 Aug 27;82(4B):11J-17J.

PMID:
9737641
[PubMed - indexed for MEDLINE]
13.

Clinical pharmacokinetics of cerivastatin.

Mück W.

Clin Pharmacokinet. 2000 Aug;39(2):99-116. Review.

PMID:
10976657
[PubMed - indexed for MEDLINE]
14.

The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.

Mück W, Park S, Jäger W, Voith B, Wandel E, Galle PR, Schwarting A.

Int J Clin Pharmacol Ther. 2001 May;39(5):192-8.

PMID:
11380064
[PubMed - indexed for MEDLINE]
15.

Pharmacokinetics of cerivastatin in renal impairment are predicted by low serum albumin concentration rather than by low creatinine clearance.

Vormfelde SV, Mück W, Freudenthaler SM, Heyen P, Schmage N, Kuhlmann J, Müller GA, Gundert-Remy UM, Gleiter CH.

J Clin Pharmacol. 1999 Feb;39(2):147-54.

PMID:
11563406
[PubMed - indexed for MEDLINE]
16.

Lack of drug-drug interaction between cerivastatin and nifedipine.

Sachse R, Brendel E, Mück W, Rohde G, Ochmann K, Horstmann R, Kuhlmann J.

Int J Clin Pharmacol Ther. 1998 Aug;36(8):409-13.

PMID:
9726692
[PubMed - indexed for MEDLINE]
17.

Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults.

Isaacsohn J, Zinny M, Mazzu A, Lettieri J, Heller AH.

Eur J Clin Pharmacol. 2001 Mar;56(12):897-903.

PMID:
11317478
[PubMed - indexed for MEDLINE]
18.

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.

Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P.

Clin Pharmacol Ther. 2000 Oct;68(4):391-400.

PMID:
11061579
[PubMed - indexed for MEDLINE]
19.

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients.

Mück W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, Neumayer HH, Kuhlmann J.

Clin Pharmacol Ther. 1999 Mar;65(3):251-61.

PMID:
10096257
[PubMed - indexed for MEDLINE]
20.

Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia.

Stein E, Sprecher D, Allenby KS, Tosiello RL, Whalen E, Ripa SR.

J Cardiovasc Pharmacol Ther. 1997 Jan;2(1):7-16.

PMID:
10684437
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk